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Original Article
Efficacy of Tamsulosin in the Treatment of Lower
Urinary Tract Symptoms (LUTS) in Women
Nithi Pummangura and Wachira Kochakarn, Division of Urology, Department of Surgery, Faculty of Medicine,
Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
OBJECTIVE: We attempted to determine whether tamsulosin is an efficacious therapy for the treatment of
lower urinary tract symptoms (LUTS) in women.
METHODS: A total of 140 women, aged 27–69 years old with LUTS entered a randomized double-blind
study comparing tamsulosin (70) versus placebo (70) for 1 month. The outcome variables were mean
change from baseline of International Prostate Symptom Score (IPSS), mean change from baseline of
mean and maximum urinary flow rate and any adverse effects.
RESULTS: Mean change from baseline of IPSS (standard deviation, SD) were −5.6 (6.3) in the tamsu-
losin group and −2.6 (6.1) in the placebo group. The difference was statistically significant (p = 0.008).
Mean change from baseline of mean urinary flow rate (SD) was 0.7 (2.7) mL/second in the tamsulosin group
and −0.5 (2.6) mL/second in the placebo group. The difference was also statistically significant (p = 0.013).
However, the difference in mean change from baseline of maximum urinary flow rate between the two
groups was not statistically significant (p = 0.506). There were two patients in the tamsulosin group who
experienced dizziness and asthenia. No other adverse effect was detected.
CONCLUSION: Tamsulosin is more efficacious than placebo in the treatment of LUTS in women. [Asian
J Surg 2007;30(2):131–7]
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Introduction
There are many drugs that have been used to treat 
lower urinary tract symptoms (LUTS) in women, such as
anticholinergics and α1-adrenergic receptor (AR) antago-
nists, but there is yet no evidence of any drugs which can
be classified among the gold standards. Despite α1-AR
antagonists not being officially registered for the treatment
of LUTS in women, they are used to relieve bothersome
symptoms in these patient groups.
Both men and women experience a similar high preva-
lence of LUTS, which increases with age.1–4 LUTS appears
to be a social problem and affects the quality of life in
almost half of affected women.4 It means that if we can
treat LUTS in women, their quality of life will improve.
LUTS also have some common underlying aetiologies in
both men and women. One of these aetiologies is that 
they have the same α1D-AR in bladder and α1A-AR in
prostate gland (men) and urethra (women) which might
be involved in causing LUTS.5 Based on these findings, 
α1-AR antagonists should theoretically be an efficacious
treatment in both men and women. Moreover, α1A/D-AR
antagonist should be more efficacious than α1A-AR
antagonist used alone.
Several randomized controlled trials have demonstrated
that tamsulosin, a new long acting selective α1A/D-AR
antagonist, is a safe and effective therapy for the treatment
of LUTS suggestive of benign prostatic obstruction (BPO)
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in men.6–11 Tamsulosin has been shown to significantly
increase urinary flow rate and improve symptom scores
and quality of life relative to placebo in men with LUTS
suggestive of BPO.
The severity of urinary symptoms associated with LUTS
has been quantified using different symptom indexes.
The International Prostate Symptom Score (IPSS) has
been validated and presently represents the most widely
accepted instrument for assessing the severity of LUTS in
men, and when captured by it, the aged-dependent preva-
lence of LUTS is equivalent in both men and women.12–14
A recent study has also shown that it is a good indicator
of the degree of bothersome symptoms and affects the
quality of life throughout various age groups of women
and is independent of coexisting incontinence.15
All of these observations suggest that the development
of LUTS might be age-specific and not gender-specific. 
If this hypothesis is valid, women with LUTS may also
benefit from tamsulosin.
Only two limited clinical studies have been reported
with α1-AR antagonists in women with LUTS.16,17 They
used α1A-AR antagonists in the treatment of women with
LUTS. The results of these studies are in different directions
and inconclusive.
We therefore performed this randomized controlled
trial to determine the efficacy of tamsulosin for the relief
of LUTS symptoms in women.
Methods
Patients and procedures
This prospective, randomized double-blind placebo con-
trolled trial was carried out at the Ramathibodi Hospital,
Faculty of Medicine, Mahidol University, between April
2004 and March 2005 (enrollment of patients ended in
February 2005). The inclusion criteria were new cases of
women with LUTS, age > 20 years, IPSS ≥ 8, normal uri-
nalysis and provision of written informed consent. The
exclusion criteria were pregnant women, stress urinary
incontinence, urinary tract infection, neurological dis-
eases including diabetes mellitus with neuropathy,
postradiation to pelvic organs, bladder cancer and con-
traindications for α1-AR antagonists. The study design was
reviewed and approved by the ethics board of the Faculty
of Medicine, Ramathibodi Hospital, Mahidol University.
Using 35% difference in mean change from baseline 
of IPSS between terazosin and placebo from the previous
study16 by assuming that tamsulosin was at least as effi-
cacious as terazosin and a power of 80%, the type I error was
set at 0.05 and the sample size in each treatment group was
set at 70. Therefore, 140 women were enrolled in the study
and were randomly allocated in 1:1 ratio to either the
tamsulosin group or to the placebo group in double blind
fashion. Block randomization size of four was carried out
by computer-generated random number and was done
before the women received any treatment. The tamsulosin
group consisted of 70 women, five of whom were lost to
follow-up (three due to symptoms not improved and two
due to adverse effect), leaving 65 women who could be eval-
uated. Of the 70 women in the placebo group, two were lost
to follow-up due to symptoms not improved. All 140 women
were included in the intention to treat analysis.
The study was conducted during a 1-month period.
Two visits were planned: an inclusion visit (D0) and end-
point visit (D30). During the treatment phase (D0–D30),
patients were randomized to receive either tamsulosin
(0.2 mg) or placebo. Study medications were packaged in
a concealed card to maintain blinding in the pharmacy
unit. Patients took one capsule daily in the evening after
food. IPSS was filled in by patients themselves using val-
idated IPSS Thai version. All uroflowmetry recordings
were carried out using the same device (Life-Tech Janus
IV®). The various uroflowmetry parameters of maximum
flow rate (mL/second), void volume (mL), and flow time
(second) were measured. Mean flow rate (mL/second) was
calculated by dividing the void volume (mL) by the flow
time (second). Uroflowmetry was considered valid if the
void volume was of at least 150 mL. If the void volume was
not sufficient, the patient was asked to drink 300–500 mL
of fluid and undergo a second uroflowmetry 1 hour later.
General clinical safety was assessed by the collection of
spontaneously reported adverse events at the end-point
visit. For compliance, the doctor asked at the end-point visit
if the treatment was taken on a regular basis and counted
the remaining tablets/drug. For co-intervention, patients
were asked at the inclusion visit not to take any other
treatment or drug for LUTS, and at the end-point visit,
the patient was asked whether she had taken other medica-
tion for the treatment of LUTS.
The primary outcome was improvement in IPSS after
4 weeks of treatment. The mean change from baseline at
the 4th week of IPSS between tamsulosin and placebo were
compared. The secondary outcomes were improvement 
in maximum and mean urinary flow rate (determined 
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by uroflowmetry). The mean changes from baseline at the 
4th week of maximum and mean urinary flow rate were
compared between tamsulosin and placebo.
Statistical analysis
All data were analysed on an intention-to-treat basis with all
recruited patients who had at least one study medication
after randomization. Missing data were checked in the data
management report. The demographic and baseline quan-
titative data were presented as mean, standard deviation,
minimum, maximum, median and quartiles as appropriate.
For the primary outcome of mean change from base-
line of IPSS, Mann–Whitney U test was used to compare
between the two treatment groups.
For the secondary outcome of mean change from
baseline of maximum and mean urinary flow rate, Mann–
Whitney U test was also used to compare between the two
treatment groups.
Adverse events were reported as numbers and 
percentages.
All statistical analyses were performed using SPSS/PC
Version 11 (SPSS Inc., Chicago, IL, USA). A two-sided signif-
icance level of 0.05 was used for all analyses.
Results
A total of 140 women with LUTS were enrolled in the
study. Seventy patients were randomly allocated to each
group (tamsulosin and placebo groups).
The baseline characteristics of the patients in both
groups were comparable regarding age, body weight,
duration, IPSS and maximum and mean urinary flow 
rate (Table 1).
Owing to a statistically significant difference in baseline
IPSS between the two groups (p = 0.001), a scatter plot
and Spearman’s rank correlation were performed. It was
found that there was a very weak correlation between base-
line IPSS and mean change from baseline in IPSS in both
groups (Spearman’s rank correlation coefficient = 0.39,
p = 0.9 in tamsulosin group and 0.31, 0.1 in placebo group
respectively). It was then assumed that the difference in
baseline IPSS between the two treatment groups had no
significant effect on difference in mean change from 
baseline in IPSS between groups.
Five patients in the tamsulosin group (7%) were lost to
follow-up due to adverse effects (2 patients) and symptoms
not improving (3 patients).
Two patients in the placebo group (2%) were lost to
follow-up due to symptoms not improving.
All the patients from both groups took the study med-
ications for 4 weeks and no other treatment of LUTS was
used during the study.
For the primary outcome, change from baseline (post–
pre) at 4th week in IPSS was analysed since improvement
in each patient’s symptom score was of interest rather
than IPSS at the end of the study. Use of change from
baseline also helped remove any difference between the
two treatment groups with regard to pretreatment IPSS.
Table 2 displays IPSS before and after treatment and the
difference in each treatment group.
Since the mean change from baseline in IPSS, mean
and maximum flow rate in both tamsulosin and placebo
groups were not normally distributed, Mann–Whitney 
U test was performed. The mean change from baseline of
IPSS in the tamsulosin group was significantly higher
than in the placebo group (−5.6 vs. −2.6, exact p = 0.008).
■ TAMSULOSIN IN WOMEN WITH LUTS ■
ASIAN JOURNAL OF SURGERY VOL 30 • NO 2 • APRIL 2007 133
Table 1. Demographic characteristics and baseline data
Tamsulosin (n = 70) Placebo (n = 70)
Mean (SD) Median Min, Max Mean (SD) Median Min, Max
Age (yr) 45.3 (12.9) 44 27, 69 49.8 (13.0) 48 27, 69
Weight (kg) 50.6 (9.3) 50 38, 67 51.8 (7.8) 50 35, 66
Duration (mo) 35.0 (34.8) 24 6, 120 38.0 (36.9) 30 4, 144
IPSS* 18.2 (5.1) 19 10, 28 21.3 (5.8) 22.5 9, 31
Max flow rate (mL/sec) 18.0 (6.1) 17 9, 30 18.8 (6.1) 19 9, 31.7
Mean flow rate (mL/sec) 7.0 (3.1) 7 3, 14.2 7.7 (3.8) 7 1, 17.3
Void volume (mL) 284.4 (118) 258 154, 482 289.9 (98.3) 283 156, 453
*p = 0.001. IPSS = International Prostate Symptom Score; SD = standard deviation; min = minimum; max = maximum.
The mean change from baseline of mean flow rate in the  
tamsulosin group was also significantly higher than in
the placebo group (0.7 vs. −0.5, exact p = 0.013) (Table 3). The
mean change from baseline of maximum flow rate in 
the tamsulosin group was not significantly higher than
in the placebo group (1.0 vs. 1.1, exact p = 0.506) (Table 4).
There was a statistically significant difference in both
mean change from baseline of IPSS and mean flow rate
but not in mean change from baseline of maximum flow
rate, there was a weak correlation among mean change
from baseline of IPSS, mean and maximum flow rate
(Spearman’s rank correlation coefficient = −0.1, p = 0.1
and −0.03, p = 0.8, respectively). However, there was a
strong correlation between mean change from baseline of
mean and maximum flow rate (Spearman’s rank correla-
tion coefficient = 0.76, p = 0.0001).
There were two patients in the tamsulosin group who
had dizziness and asthenia (2%) and were lost to follow-up.
No patient in the placebo group had adverse effect.
Discussion
LUTS in women, including urinary incontinence, is
highly prevalent in the community (up to half of women
may have some degree of urinary incontinence),1–4 but it
is considerably under-diagnosed and treated. There are
many drugs which have been used to treat LUTS in
women such as anticholinergics and α1-AR antagonists,
but there is no evidence to know which drugs are used for
standard treatments. The rationale for investigating α1-AR
antagonists for the treatment of women with LUTS was
based upon the observation that men and women had the
same propensity for LUTS, suggesting that some aetiolo-
gies might be identical. Recently, data have clearly shown
that the human prostate (female urethra) predominantly
expressed α1A-ARs and human detrusor contains mainly
α1D-ARs, although the expression of α1-ARs, is low.18 α1D-
ARs, which are predominately present in the spinal cord,
might also be involved in the development of LUTS.19
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Table 2. Comparison of International Prostate Symptom score between two treatments
Baseline (Pre) Post-treatment Difference (Post − pre)
Mean (SD) Median Min, Max Mean (SD) Median Min, Max Mean (SD) Median Min, Max
Tamsulosin (n = 65) 18.2 (5.1) 19 10, 28 12.6 (9.1) 10 3, 28 −5.6 (6.3) −5 7, −17
Placebo (n = 68) 21.3 (5.8) 22.5 9, 31 18.7 (9.7) 21 2, 32 −2.6 (6.1) −4 7, −16
SD = standard deviation; min = minimum; max = maximum.
Table 3. Comparison of mean flow rate (mL/sec) between two treatments
Baseline (Pre) Post-treatment Difference (Post − pre)
Mean (SD) Median Min, Max Mean (SD) Median Min, Max Mean (SD) Median Min, Max
Tamsulosin (n = 65) 7.0 (3.2) 7 3, 14.2 7.7 (3.4) 9 4, 20 0.7 (2.7) 1 −5.2, 5
Placebo (n = 68) 7.9 (3.8) 7 1, 17.3 7.4 (3.5) 6 1, 13.6 −0.5 (2.6) −1 −6.5, 3
SD = standard deviation; min = minimum; max = maximum.
Table 4. Comparison of maximum flow rate (mL/sec) between two treatments
Baseline (Pre) Post-treatment Difference (Post − pre)
Mean (SD) Median Min, Max Mean (SD) Median Min, Max Mean (SD) Median Min, Max
Tamsulosin (n = 65) 18.0 (6.5) 17 9, 30 19.0 (5.2) 17 12, 28.6 1.0 (4.2) 1 −3.8, 12
Placebo (n = 68) 19.0 (5.9) 19 9, 31.7 20.1 (10) 17 9, 46.5 1.1 (8.1) −1 −11.4, 22.1
SD = standard deviation; min = minimum; max = maximum.
Moreover, the α1A-ARs in prostate (female urethra) might
be involved in producing bladder outlet obstruction and
the α1D-AR in the bladder might be the subtype responsible
for bladder overactivity.
These would furthermore suggest that an α1A/D-selective
compound such as tamsulosin20 would be expected to
reduce both obstruction and improve voiding and storage
symptoms in women as issues that are well documented
in the controlled clinical trials with this compound in
men.6–11
Only limited clinical studies have been reported with
α1A-AR antagonists in women with LUTS.16,17 One placebo-
controlled study showed no better effects of the α1A-AR
antagonist terazosin in 29 women. This study used α1A-
AR antagonist not α1A/D-AR antagonist and was under-
powered to detect clinical significance. Another study was
an open nonrandomized trial that used α1A-AR antago-
nist doxazosin. This study showed that the α1A-AR antag-
onist doxazosin is at least as effective as anticholinergic
hyoscyamine in reducing the total IPSS (−30% vs. −34%,
respectively). Similarly, a very small open Japanese 
study in five women with LUTS suggested that tamsu-
losin reduced the total IPSS and residual volume, and
improved the quality of life and urinary flow rate in
women with LUTS.
To our knowledge, our study represented the only ran-
domized placebo-controlled trial to investigate the thera-
peutic benefit of an α1A/D-AR antagonist tamsulosin in
women with LUTS. A total of 140 patients were enrolled
in the study which reached the power of 80% to detect
clinical significance. Seventy patients were randomly allo-
cated to tamsulosin and placebo groups. The baseline
characteristics of patients in each group was not statistically
significant except for baseline IPSS which was higher in
the placebo group than in the tamsulosin group (p = 0.001).
Owing to this significant difference, scatter plot and
Spearman’s rank correlation were performed and it was
found that there was a very weak correlation between
baseline IPSS and mean change of IPSS in both groups.
We then assumed that the difference in baseline IPSS
between the two treatment groups had no significant
effect on the difference in mean change from baseline in
IPSS between groups.
The primary outcome in the study was mean change
from baseline of IPSS. Our study showed that there was a
statistically significant difference in mean change from
baseline of IPSS between the tamsulosin and placebo
groups, but that might not be clinically significant because
the difference in mean change of IPSS was only 3 points.
Similar analyses were performed for the voiding and storage
part of IPSS. These were both not statistically significant
(results not shown). These results imply that improvement
in total IPSS may be the components of both voiding and
storage symptoms.
The secondary outcome in the study was mean change
from baseline of mean and maximum flow rate. Our study
showed that there was a statistically significant difference
in mean change from baseline of mean flow rate between
the tamsulosin and placebo groups but not in mean
change from baseline of maximum flow rate independent
of void volume. There was no statistically significant dif-
ference among baseline, post-treatment and difference in
void volume in both groups (results not shown). The
changes in the flow rate are perhaps not clinically signifi-
cant despite statistical significance (at least for the changes
in the mean flow rate). Therefore, the improvement in
IPSS may not be due to improvements in flow rates.
Although there was a statistically significant differ-
ence in both mean changes from baseline of IPSS and
mean flow rate but not in mean change from baseline of
maximum flow rate, there was a weak correlation among
mean change from baseline of IPSS, mean and maximum
flow rate. However, there was a strong correlation between
mean and maximum flow rate.
These findings also suggest that the level of improve-
ment in urinary symptoms was not directly related to the
improvement in urinary flow rate, indicating that the mech-
anism for symptom improvement might not be mediated
exclusively by relieving bladder outlet obstruction.
All of these findings were different from the previous
studies16 because our study was more detailed and used
tamsulosin (α1A/D-AR antagonist) that theoretically is
more efficacious than α1A-AR antagonist.
Overall, tamsulosin was fairly well tolerated at the daily
single dose of 0.2 mg. Asthenia and dizziness developed
in two patients in the tamsulosin group and was suffi-
ciently troublesome to result in premature withdrawal from
the study. No patient in the placebo group developed 
side effects.
A criticism of the study was the primary outcome
(mean change from baseline of IPSS). IPSS was a surro-
gate outcome that might not reflect the actual benefit 
to the patients from taking the α1A/D-AR antagonist tam-
sulosin. Quality of life would have been more appropriate.
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IPSS was also a subjective outcome. Despite trying to
minimize the bias when filling the IPSS, there were some
misunderstandings of the patients that reflected the reli-
ability of the IPSS. The last one is that the study should
have included anticholinergics that have been used to
treat LUTS in women efficaciously so that there were
three treatments in the study to make the results more
interpretable.
This study suggested that the α1A/D-AR antagonist
tamsulosin was more efficacious for relieving LUTS than
placebo in an unselected female population. It could
improve IPSS and urinary flow rate but there was no corre-
lation between them suggesting that improving only uri-
nary flow rate did not mean that tamsulosin could clinically
improve IPSS that was the major problem in the female
patients and vice versa. Although men and women had
the same predisposition for LUTS, the pathophysiology
for the symptomatology was gender-specific. It was con-
ceivable that a subgroup of women with LUTS (that was
women with bladder neck dysfunction) might respond to
selective α1A/D-AR antagonists (improve urinary flow rate
and IPSS). Based on this study, tamsulosin should be
used carefully in selected female patients because of its
rather low efficacy and high cost.
Further studies should be directed towards a subgroup
of female patients with bladder neck dysfunction, com-
paring tamsulosin with anticholinergics and determining
the pathophysiology of urinary symptoms in women, which
may lead to the development of new pharmacological
strategies for treating LUTS.
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